Evidence map›Paper›PMID 34206978›Full record

ReviewDiagnostics (Basel, Switzerland)2021

Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe.

Tatjana Huebner, Catharina Scholl, Michael Steffens

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tatjana HuebnerResearch Division, Federal Institute for Drugs and Medical Devices, 53175 Bonn, North Rhine-Westphalia, Germany.
Catharina SchollResearch Division, Federal Institute for Drugs and Medical Devices, 53175 Bonn, North Rhine-Westphalia, Germany.ORCID 0000-0002-1463-5619
Michael SteffensResearch Division, Federal Institute for Drugs and Medical Devices, 53175 Bonn, North Rhine-Westphalia, Germany.ORCID 0000-0002-6445-8593
Federal Institute for Drugs and Medical Devices · DE

Funding

Bundesministerium für Gesundheit ZMVI1-2519FSB404
6 · The paper itself

Abstract

For many authorized drugs, accumulating scientific evidence supports testing for predictive biomarkers to apply personalized therapy and support preventive measures regarding adverse drug reactions and treatment failure. Here, we review cytogenetic and biochemical genetic testing methods that are available to guide therapy with drugs centrally approved in the European Union (EU). We identified several methods and combinations of techniques registered in the Genetic Testing Registry (GTR), which can be used to guide therapy with drugs for which pharmacogenomic-related information is provided in the European public assessment reports. Although this registry provides information on genetic tests offered worldwide, we identified limitations regarding standard techniques applied in clinical practice and the information on test validity rarely provided in the according sections.

Indexed as

companion diagnosticin vitro diagnosticpersonalized therapypharmacogeneticspharmacogenomicsregulation

Identifiers

PMID34206978
PMCPMC8303692
OpenAlexW3175939983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.